Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
Introduction The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with heterozygous familial hypercholesterolemia or...
Main Authors: | Maciej Banach, José Luis López-Sendon, Maurizio Averna, Bertrand Cariou, Megan Loy, Garen Manvelian, Isabela Batsu, Yann Poulouin, Daniel Gaudet |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2021-10-01
|
Series: | Archives of Medical Science |
Subjects: | |
Online Access: | https://www.archivesofmedicalscience.com/Treatment-adherence-and-effect-of-concurrent-statin-intensity-on-the-efficacy-and,143476,0,2.html |
Similar Items
-
Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
by: Shaun G. Goodman, et al.
Published: (2023-09-01) -
Effect of alirocumab on cataracts in patients with acute coronary syndromes
by: Gaspard Suc, et al.
Published: (2023-06-01) -
Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
by: Maciej Banach, et al.
Published: (2023-06-01) -
Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
by: Hui-Chun Huang, et al.
Published: (2022-07-01) -
Mortality Benefit of Alirocumab: A Bayesian Perspective
by: Christopher Labos, et al.
Published: (2019-10-01)